DadFinStart your free weekHumacyte, Inc. (HUMA) stock score
$0.41 ▼ -9.33% today
Humacyte, Inc. (HUMA) is a Biotechnology company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 36.4 out of 100 on the Dad Score, a weak reading that places the business ahead of 36% of the 5,773 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #543 of 968. Its strongest axes are quality and growth; its weakest are valuation and price action.
Scores from the run of Oct 11, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →
The eight axes
Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.
Key numbers
What subscribers see on HUMA
- Value Score: is the price right for this business, the score the Value book is selected on.
- Trader Score: is it set up to move, refreshed every 15 minutes in the session.
- The full eight-axis breakdown, every input and its percentile.
- SEC filings, insider buying, earnings history and peers side by side.
- Whether it is in this week's published books, with the receipts.
Biotechnology peers
| Stock | Company | Dad Score | Band |
|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Incorporate | 65.2 | middling |
| MRNA | Moderna, Inc. | 34.4 | weak |
| REGN | Regeneron Pharmaceuticals, Inc. | 91.6 | strong |
| ARGX | argenx SE | 60.2 | middling |
| RVMD | Revolution Medicines, Inc. | 31.2 | weak |
| ONC | BeOne Medicines AG | 79.2 | good |
| RPRX | Royalty Pharma plc | 66.7 | middling |
| ALNY | Alnylam Pharmaceuticals, Inc. | 89.1 | strong |
Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 11, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.